Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | G6PD | P11413 | 4/20 | 0.49 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.49 |
| ▸ | IGF2R | P11717 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | CA9 | Q16790 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5679954 | 1.00 | G6PD (0.49) | G6PDLGALS8IGF2RCA1CA2 | |
| SCHEMBL19656076 | 0.87 | LGALS8 (0.49) | G6PDLGALS8CA1CA2CA9 | |
| SCHEMBL13857700 | 0.87 | LGALS8 (0.46) | G6PDLGALS8IGF2RCA1CA2 | |
| SCHEMBL5681074 | 0.85 | G6PD (0.50) | G6PDLGALS8CA1CA2CA9 | |
| SCHEMBL9216351 | 0.85 | LGALS8 (0.51) | LGALS8IGF2R | |
| SCHEMBL21711019 | 0.84 | IGF2R (0.63) | G6PDLGALS8IGF2RCA1CA2 | |
| SCHEMBL21707016 | 0.84 | IGF2R (0.63) | G6PDLGALS8IGF2RCA1CA2 | |
| SCHEMBL12598611 | 0.81 | G6PD (0.47) | G6PDLGALS8CA1CA2CA9 | |
| SCHEMBL13632489 | 0.81 | G6PD (0.47) | G6PDLGALS8CA1CA2CA9 | |
| SCHEMBL21769310 | 0.81 | G6PD (0.43) | G6PDLGALS8IGF2RCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210275510-A1 | PYRIDINE DERIVATIVES SUBSTITUTED BY HETEROCYCLIC RING AND AMINO GROUP | BASILEA PHARMACEUTICA INTERNATIONAL AG, ALLSCHWIL (CH) | 2021-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210275510-A1 | PYRIDINE DERIVATIVES SUBSTITUTED BY HETEROCYCLIC RING AND AMINO GROUP | ERG28, PDXK, PAH | G6PD 5/4885LGALS8 2567/4885IGF2R 2236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.